ANEBULO PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Increase (Decrease) in Accrued Liabilities of $667.27 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $574.50K, a 137.20% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $92.77K, a 56.43% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was $145.06K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was -$440.83K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $159.36K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$430.10K, a 206.84% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $402.55K, a 341046.61% increase from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $118.00, a 99.89% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 2 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $574.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $667.27K 10-Q · filed 2026-02-12 | $812.33K derived: sum of 3 quarters · filed 2026-02-12 | $371.50K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | $92.77K 10-Q · filed 2025-11-13 | $237.83K derived: sum of 2 quarters · filed 2025-11-13 | -$203.00K derived: sum of 3 quarters · filed 2025-11-13 | $39.20K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-06-30 | $145.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$295.77K derived: sum of 2 quarters · filed 2025-09-29 | -$53.57K derived: sum of 3 quarters · filed 2026-02-12 | $159.36K 10-K · filed 2025-09-29 | |
| 2025-03-31 | -$440.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$198.63K derived: sum of 2 quarters · filed 2026-02-12 | $14.30K 10-Q · filed 2025-05-13 | -$506.95K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | $242.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $455.13K 10-Q · filed 2026-02-12 | -$66.12K derived: sum of 3 quarters · filed 2026-02-12 | -$135.59K derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-09-30 | $212.93K 10-Q · filed 2025-11-13 | -$308.32K derived: sum of 2 quarters · filed 2025-11-13 | -$377.79K derived: sum of 3 quarters · filed 2025-11-13 | $166.47K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$521.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$590.72K derived: sum of 2 quarters · filed 2025-09-29 | -$46.45K derived: sum of 3 quarters · filed 2025-09-29 | -$430.10K 10-K · filed 2025-09-29 | |
| 2024-03-31 | -$69.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $474.79K derived: sum of 2 quarters · filed 2025-05-13 | $91.14K 10-Q · filed 2025-05-13 | -$294.78K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $544.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $160.62K 10-Q · filed 2025-02-14 | -$225.31K derived: sum of 3 quarters · filed 2025-02-14 | -$330.97K derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | -$383.64K 10-Q · filed 2024-11-13 | -$769.57K derived: sum of 2 quarters · filed 2024-11-13 | -$875.24K derived: sum of 3 quarters · filed 2024-11-13 | -$24.09K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$385.93K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | -$491.59K derived: sum of 2 quarters · filed 2024-09-25 | $359.55K derived: sum of 3 quarters · filed 2024-09-25 | $402.55K 10-K · filed 2024-09-25 | |
| 2023-03-31 | -$105.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $745.48K derived: sum of 2 quarters · filed 2024-05-15 | $788.48K 10-Q · filed 2024-05-15 | $917.68K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | $851.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $894.14K 10-Q · filed 2024-02-13 | $1.02M derived: sum of 3 quarters · filed 2024-02-13 | $1.02M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | $43.00K 10-Q · filed 2023-11-14 | $172.21K derived: sum of 2 quarters · filed 2023-11-14 | $167.71K derived: sum of 3 quarters · filed 2023-11-14 | $60.82K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $129.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $124.70K derived: sum of 2 quarters · filed 2023-09-22 | $17.82K derived: sum of 3 quarters · filed 2023-09-22 | $118.00 10-K · filed 2023-09-22 | |
| 2022-03-31 | -$4.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$111.39K derived: sum of 2 quarters · filed 2023-05-11 | -$129.09K 10-Q · filed 2023-05-11 | -$208.64K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$106.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | -$124.58K 10-Q · filed 2023-02-10 | -$204.14K derived: sum of 3 quarters · filed 2023-02-10 | -$52.95K derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | -$17.70K 10-Q · filed 2022-11-10 | -$97.25K derived: sum of 2 quarters · filed 2022-11-10 | $53.94K derived: sum of 3 quarters · filed 2022-11-10 | $40.70K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$79.55K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $71.64K derived: sum of 2 quarters · filed 2022-09-09 | $58.40K derived: sum of 3 quarters · filed 2022-09-09 | $109.01K 10-K · filed 2022-09-09 | |
| 2021-03-31 | $151.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | $137.95K derived: sum of 2 quarters · filed 2022-05-11 | $188.56K 10-Q · filed 2022-05-11 | ||
| 2020-12-31 | -$13.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | $37.37K 10-Q · filed 2022-02-11 | |||
| 2020-09-30 | $50.61K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $22.58K 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |